Jump to content

Lansoprazole

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Swelgemoed (talk | contribs) at 14:43, 11 July 2011 (→Pharmacology). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Lansoprazole
Clinical data
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Oral, IV
ATC code
Legal status
Legal status
  • US: WARNING[1]OTC
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability80% or more
Protein binding97%
MetabolismHepatic (CYP3A4- and CYP2C19-mediated)
Elimination half-life1–1.5 hours
ExcretionRenal and fecal
Identifiers
  • (RS)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.173.220 Edit this at Wikidata
Chemical and physical data
FormulaC16H14F3N3O2S
Molar mass369.363 g/mol g·mol−1
3D model (JSmol)
  • FC(F)(F)COc1c(c(ncc1)CS(=O)c3nc2ccccc2n3)C
  • InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22) checkY
  • Key:MJIHNNLFOKEZEW-UHFFFAOYSA-N checkY
  (verify)

Lansoprazole (Template:Pron-en lan-SOH-prə-zohl, INN) is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid. It is manufactured by a number of companies worldwide under several brand names (some brand names include: Prevacid, Helicid, Zoton, Inhibitol, Monolitum). It was first approved by the U.S. Food and Drug Administration (FDA) in 1995.[2]

Prevacid patent protection expired on November 10, 2009.[3][4] As a result, prescription Lansoprazole is now available in the form of a generic drug. As of November 12, 2009, Lansoprazole is available over-the-counter (OTC) in the U.S. in a 15 mg dose marketed by Novartis as Prevacid 24HR.[5][6][7]

Currently (November 25, 2009) in the U.S, prescription Lansoprazole and OTC Prevacid sell for about 50% and 25% respectively of the cost of prescription Prevacid.

Pharmacology

Main article: Proton-pump inhibitor

Lansoprazole is a proton-pump inhibitor (PPI) in the same pharmacologic class as omeprazole. Lansoprazole has been marketed for many years and is one of several PPIs available.[8] Lansoprazole is a racemate [1:1-mixture of the enantiomers dexlansoprazole (Kapidex) and levolansoprazole].[9] Dexlanprantazole is an enantiomerically pure active ingredient of a commercial drug as a result of the 'enantiomeric shift'.

Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects (i.e. gastric acid suppression). The mean plasma elimination half-life is 1.5 hours,[10] and the effects of the drug last for over 24 hours after it has been used for 1 day or more.[11] Lansoprazole, 30 mg administered nasogastrically, effectively controls intragastric pH and is an alternative to i.v. pantoprazole in patients who are unable to swallow solid dosage formulations.[12]

Indications

Lansoprazole is indicated for:

Drug interactions

Side effects

Proton-pump inhibitors may be associated with a greater risk of hip fractures,[16] clostridium difficile-associated diarrhea.[17] Patients are frequently administered the drugs in intensive care as a protective measure against ulcers, but this use is also associated with a 30% increase in occurrence of pneumonia.[18]

Brand names

Prevacid 30 mg

The drug is sold under several brand names, including:[2]

  • Agopton (Germany)
  • Lansor (Turkey)
  • Digest (Indonesia)
  • Duogast (Syria)
  • Gastrolan (Indonesia)
  • Lansobene (Austria)
  • Lenzo (India)
  • Lanzol (India)
  • Lanzotec (Jordan)
  • Lanzul (Slovenia)
  • Lansazol (Jordan)
  • Lansoptol (Hungary)
  • Lansox (Italy)
  • Lansoloc (South Africa)
  • Lanston LFDT (South Korea)
  • Lanton (Israel)
  • Lanzo (Sweden)
  • Lanzor (France, South Africa)
  • Lanzostad (Lithuania, Latvia, Estonia)
  • Laprazol (Greece)
  • Lanciprol (Greece)
  • Limpidex (Italy)
  • Monolitum (Spain)
  • Ogast and OgastORO (France)
  • Ogastro (Mexico)
  • Prevacid (U.S. and Canada) Prevacid is a product of Takeda Pharmaceuticals.
  • Prevacid 24HR (U.S.)
  • pro-ulco (Spain)
  • Prosogan and Prosogan FD (Indonesia)
  • Refluxon (Hungary)
  • SOLOX (New Zealand)
  • Takepron (Japan)
  • Zolt (Finland)
  • Zoton (Italy, Ireland, Australia, UK)
  • ZOMEL (Ireland)

Lansoprazole is also available as a generic drug in the US, UK, Canada, Belgium, Finland,[19] France, Colombia, Italy, Sweden,[20] and Mexico.[citation needed]

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved October 22, 2023.
  2. ^ a b Mosby's Drug Consult: Lansoprazole
  3. ^ Prevacid drug patents
  4. ^ Teva to release Prevacid version when patent expires
  5. ^ "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (PDF) (Press release). November 12, 2009. Retrieved November 13, 2009.
  6. ^ "Prevacid 24HR Patient Package Insert" (PDF). November 12, 2009. Retrieved November 13, 2009.
  7. ^ "Novartis launches Prevacid 24HR over-the-counter for full 24-hour frequent heartburn treatment" (Press release). November 12, 2009. Retrieved November 13, 2009.
  8. ^ http://www.patient.co.uk/showdoc/30002943/
  9. ^ http://www.mainecarepdl.org/index.pl/genpharmfiles/memos-and-mailings/pharmacy-benefit-update-summer-fall-2009.pdf
  10. ^ a b "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism". RxList.com. 2007. Retrieved April 14, 2007. Cite error: The named reference "RxList" was defined multiple times with different content (see the help page).
  11. ^ "Prevacid 24HR Fact Sheet" (PDF). November 12, 2009. Retrieved November 13, 2009.
  12. ^ Effects on 24-Hour Intragastric pHFreston, James (2001). "Effects on 24-Hour Intragastric pH: A Comparison of Lansoprazole Administered Nasogastrically in Apple Juice and Pantoprazole Administered Intravenously". THE AMERICAN JOURNAL OF GASTROENTEROLOGY. 96 (7). ISSN 0002-9270/01/$20.00. {{cite journal}}: Check |issn= value (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |pii= ignored (help); line feed character in |title= at position 36 (help)
  13. ^ Antimicrob Agents Chemother. 1991 September; 35(9): 1765–1771. Effects of ranitidine and sucralfate on ketoconazole bioavailability. S C Piscitelli, T F Goss, J H Wilton, D T D'Andrea, H Goldstein, and J J Schentag [1]
  14. ^ K C Singhal & S Z Rahman, Lansoprazole Induced Adverse Effects on the Skin, Indian Medical Gazette, July 2001, Vol. CXXXV. N0. 7: 223-225
  15. ^ Sterry W, Assaf C (2007). "Erythroderma". In Bolognia JL (ed.). Dermatology. St. Louis: Mosby. p. 154. ISBN 1-4160-2999-0.
  16. ^ Yang YX, Lewis JD, Epstein S, Metz DC (2006). "Long-term proton pump inhibitor therapy and risk of hip fracture". JAMA. 296 (24): 2947–53. doi:10.1001/jama.296.24.2947. PMID 17190895. {{cite journal}}: |access-date= requires |url= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  17. ^ "Proton pump inhibitors and Clostridium difficile". Bandolier. 2003. Retrieved July 13, 2007.
  18. ^ Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (2009). "Acid-suppressive medication use and the risk for hospital-acquired pneumonia". JAMA. 301 (20): 2120–8. doi:10.1001/jama.2009.722. PMID 19470989. {{cite journal}}: |access-date= requires |url= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  19. ^ "Vastaavat tuotteet - hintavertailu" (in Finnish).
  20. ^ "FASS.se, accessed 2010-02-13" (in Swedish).
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lansoprazole&oldid=438916745"